Health Headlines: Shifts in Drug Approvals and Illness Exposures on Rise

In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and EU approves early Alzheimer's drug. Meanwhile, 800 million adults face untreated diabetes, and global measles cases soar due to inadequate vaccination, reflecting varied health challenge narratives.

Novo Nordisk is gradually discontinuing the manufacture of human insulin pens globally, as it invests heavily in obesity and diabetes injection production. The company has not provided a timeline, spokesperson confirms. Human insulin will soon be available only in vials.

As Donald Trump assembles his administration, Robert F. Kennedy Jr. emerges as a potential pick to lead the Department of Health and Human Services, according to Politico. This comes after Kennedy, an independent candidate in the recent election cycle, endorsed Trump in exchange for a role.

In the pharmaceutical world, the EU drugs regulator recently reversed an earlier decision by recommending the approval of Eisai and Biogen's Leqembi for early Alzheimer's disease. This approval, if accepted by the European Commission, could mark the EU's first treatment break in Alzheimer's care.

(With inputs from agencies.)